A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder (STRIDE-1)
STRIDE-1: A Randomized, Double-blind, Active-controlled Trial to Assess the Efficacy and Safety of AXS-05 Administered Orally to Subjects With Treatment Resistant Major Depressive Disorder
Sponsor: Axsome Therapeutics, Inc.
A PHASE3 clinical study on Treatment Resistant Major Depressive Disorder, this trial is completed. The trial is conducted by Axsome Therapeutics, Inc. and has accumulated 16 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Apr 2021 — Apr 2022 [monthly]
Completed PHASE3
▶ Show 11 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Completed PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2018 — Feb 2020 [monthly]
Recruiting PHASE3
-
Oct 2018 — Dec 2018 [monthly]
Recruiting PHASE3
-
Jul 2018 — Oct 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Sep 2017 — Mar 2018 [monthly]
Recruiting PHASE3
-
Feb 2017 — Sep 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Mar 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Axsome Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .